10x Genomics, Inc.: insider trades · United States · SEC (Form 4)

About 10x Genomics, Inc.

10x Genomics, Inc. is a U.S.-based life-science tools company listed on the NASDAQ under the ticker TXG, with headquarters in Pleasanton, California, United States. For French, Belgian, and Swiss investors, the company sits in an attractive niche of the healthcare and research-tools universe: it provides technologies that help scientists study biology at the resolution of individual cells and within the spatial context of tissue. Founded in 2012 by Serge Saxonov and Ben Hindson, 10x Genomics has become one of the most recognized brands in single-cell and spatial biology, especially in academic and translational research settings. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) The company’s business model is built around instruments, consumables, reagents, software, and workflows used to profile cells and tissues for research purposes. Its core platforms are Chromium for single-cell analysis, Visium for spatial transcriptomics, and Xenium for in situ analysis. These products are designed to generate high-resolution biological data for fields such as oncology, immunology, neuroscience, and developmental biology. In practical terms, this gives 10x Genomics exposure to the research and discovery spending cycle rather than to routine clinical diagnostics, which is an important point for investors assessing demand volatility and the pace of adoption. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) From a competitive standpoint, 10x Genomics has built a strong reputation around data quality, workflow integration, and a broad scientific ecosystem. The company highlights more than 10,000 publications, a large installed base of instruments, and a global footprint spanning the United States, Europe, and Asia, including locations in the Netherlands, Taiwan, China, and Singapore. This international presence supports commercial reach and helps the company serve major research institutions worldwide. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) Recent news has centered on product innovation and portfolio expansion. In 2024, 10x Genomics launched major new products across all three platforms, including Chromium GEM-X, Visium HD, and Xenium Prime 5K. In its February 2025 earnings release, the company reported full-year 2024 revenue of $610.8 million and cash and marketable securities of $393.4 million at year-end, while also noting a challenging macro backdrop. It also announced the Billion Cells Project with the Chan Zuckerberg Initiative and Ultima Genomics, underscoring its strategic role in building large-scale biological datasets and advancing AI-enabled biology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/txg-fy2024earningsreleasee.htm?utm_source=openai))